Literature DB >> 28201738

A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis.

Masako Ueda1, Richard L Dunbar1, Anna Wolska2, Tracey U Sikora1, Maria Del Rosario Escobar1, Naomi Seliktar1, Emil deGoma3, Stephanie DerOhannessian1, Linda Morrell1, Adam D McIntyre4, Frances Burke5, Denis Sviridov2, Marcelo Amar2, Robert D Shamburek2, Lita Freeman2, Robert A Hegele4, Alan T Remaley2, Daniel J Rader1.   

Abstract

Context: Familial chylomicronemia syndrome (FCS) is a rare heritable disorder associated with severe hypertriglyceridemia and recurrent pancreatitis. Lipoprotein lipase deficiency and apolipoprotein C-II deficiency are two well-characterized autosomal recessive causes of FCS, and three other genes have been described to cause FCS. Because therapeutic approaches can vary according to the underlying etiology, it is important to establish the molecular etiology of FCS. Case Description: A man originally from North Africa was referred to the University of Pennsylvania Lipid Clinic for severe hypertriglyceridemia and recurrent pancreatitis, consistent with the clinical diagnosis of FCS. Molecular analyses of FCS-associated genes revealed a homozygous missense variant R72T in APOC2. Molecular modeling of the variant predicted that the apolipoprotein C-II R72T peptide has reduced lipid binding affinity. In vitro studies of the patient's plasma confirmed the lack of functional apoC-II activity. Moreover, the apoC-II protein was undetectable in the patient's plasma, quantitatively as well as qualitatively. Conclusions: We identified a missense APOC2 variant causing apoC-II deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Beyond dietary management and usual pharmacologic therapies, an apoC-II mimetic peptide may become an optional therapy in patients with apoC-II deficiency in the future.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28201738      PMCID: PMC6283445          DOI: 10.1210/jc.2016-3903

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.

Authors:  Daniel Gaudet; Erik S Stroes; Julie Méthot; Diane Brisson; Karine Tremblay; Sophie J Bernelot Moens; Giorgio Iotti; Irene Rastelletti; Diego Ardigo; Deyanira Corzo; Christian Meyer; Marc Andersen; Philippe Ruszniewski; Mark Deakin; Marco J Bruno
Journal:  Hum Gene Ther       Date:  2016-07-13       Impact factor: 5.695

3.  A molecular theory of lipid-protein interactions in the plasma lipoproteins.

Authors:  J P Segrest; R L Jackson; J D Morrisett; A M Gotto
Journal:  FEBS Lett       Date:  1974-01-15       Impact factor: 4.124

4.  Familial apolipoprotein CII deficiency: plasma lipoproteins and apolipoproteins in heterozygous and homozygous subjects and the effects of plasma infusion.

Authors:  N E Miller; S N Rao; P Alaupovic; N Noble; J Slack; J D Brunzell; B Lewis
Journal:  Eur J Clin Invest       Date:  1981-02       Impact factor: 4.686

Review 5.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

6.  Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase.

Authors:  J Zdunek; G V Martinez; J Schleucher; P O Lycksell; Y Yin; S Nilsson; Y Shen; G Olivecrona; S Wijmenga
Journal:  Biochemistry       Date:  2003-02-25       Impact factor: 3.162

7.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

Authors:  Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

8.  LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias.

Authors:  Christopher T Johansen; Joseph B Dubé; Melissa N Loyzer; Austin MacDonald; David E Carter; Adam D McIntyre; Henian Cao; Jian Wang; John F Robinson; Robert A Hegele
Journal:  J Lipid Res       Date:  2014-02-06       Impact factor: 5.922

  8 in total
  13 in total

1.  Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis at the National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Mark E Lowe; Marc T Goodman; Gregory A Coté; Marshall J Glesby; Mark Haupt; Nicholas J Schork; Vikesh K Singh; Dana K Andersen; Stephen J Pandol; Aliye Uc; David C Whitcomb
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

2.  Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis.

Authors:  Xunde Xian; Yuhui Wang; George Liu
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

Review 4.  Endothelial Cell Receptors in Tissue Lipid Uptake and Metabolism.

Authors:  Nada A Abumrad; Ainara G Cabodevilla; Dmitri Samovski; Terri Pietka; Debapriya Basu; Ira J Goldberg
Journal:  Circ Res       Date:  2021-02-04       Impact factor: 17.367

5.  Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin.

Authors:  Marissa Lightbourne; Anna Wolska; Brent S Abel; Kristina I Rother; Mary Walter; Yevgeniya Kushchayeva; Sungyoung Auh; Robert D Shamburek; Alan T Remaley; Ranganath Muniyappa; Rebecca J Brown
Journal:  J Endocr Soc       Date:  2020-12-04

Review 6.  Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.

Authors:  Gissette Reyes-Soffer; Marit Westerterp
Journal:  Pharmacol Res       Date:  2021-05-23       Impact factor: 10.334

Review 7.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

8.  Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice.

Authors:  Tomohiro Komatsu; Toshihiro Sakurai; Anna Wolska; Marcelo J Amar; Akiko Sakurai; Boris L Vaisman; Denis Sviridov; Stephen Demosky; Milton Pryor; Katsunori Ikewaki; Alan T Remaley
Journal:  J Nutr Metab       Date:  2019-02-03

9.  Eruptive xanthoma model reveals endothelial cells internalize and metabolize chylomicrons, leading to extravascular triglyceride accumulation.

Authors:  Ainara G Cabodevilla; Songtao Tang; Sungwoon Lee; Adam E Mullick; Jose O Aleman; M Mahmood Hussain; William C Sessa; Nada A Abumrad; Ira J Goldberg
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 19.456

Review 10.  Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.

Authors:  Debapriya Basu; Karin E Bornfeldt
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.